N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide has been researched along with plx4032 in 1 studies
Studies (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Trials (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Recent Studies (post-2010) (N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
---|---|---|---|---|---|
9 | 0 | 7 | 1,657 | 103 | 1,587 |
Protein | Taxonomy | N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide (IC50) | plx4032 (IC50) |
---|---|---|---|
Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide and plx4032
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |